ArticleEJNMMI reports2026

Quantitative bone SPECT/CT-derived tumor burden as a prognostic biomarker in metastatic castration-resistant prostate cancer treated with Ra-223.

Yoshimitsu Fukushima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.